Piecemeal mucosectomy, submucosal dissection or transanal microsurgery for large colorectal neoplasm by AREZZO, Alberto et al.
  
 
 
This is the accepted version of the following article:  
Colorectal Disease 17(1):44-51,2015 
 
which has been published in final form at  
http://onlinelibrary.wiley.com/doi/10.1111/codi.12821/pdf  
 
 
Piecemeal mucosectomy, submucosal dissection or transanal microsurgery for 
large colorectal neoplasm 
1. A. Arezzo1,*, T. Matsuda2, B. Rembacken3, W. F. A. Miles4, G. Coccia5 and Y. Saito2 
Introduction 
Although smaller colonic polyps are removed by snare polypectomy or Endoscopic 
Mucosal Resection (EMR), there is evidence from the British Bowel Cancer Screening 
Programme that many larger lesions are referred for surgical resection. There is, however, 
a significant morbidity and mortality attached to surgery, with 30 day mortality rates varying 
between 1% and 8% [1]. In addition, surgery is expensive. In the UK, the surgical 
treatment of colonic lesions accounts for more hospital in-patient expenditure than for 
cancer at any other site. 
In contrast to surgical resection, endoscopic resection allows colonic lesions to be 
removed with a minimum of cost, morbidity and mortality [2-4]. The recognition and 
removal of precancerous lesions are important to reduce the risk of subsequent colorectal 
cancer [5]. Furthermore, many likely early colonic cancers are considered for removal by 
endoscopic resection such as EMR or Endoscopic Submucosal Dissection (ESD) [6]. EMR 
is now a well-established technique for the treatment of colorectal neoplasms with minimal 
invasiveness [7, 8, 2]. However, it entails a high frequency of local recurrence after 
piecemeal EMR for large lesions [9, 10]. ESD was conceived in Japan with the aim to 
avoid this problem, allowing en bloc resection of larger colorectal lesions. Despite its 
longer procedure time and higher complication rate, ESD results in a higher en bloc 
resection rate compared with conventional or piecemeal EMR [11-13]. ESD for colorectal 
lesions is not yet fully established as a standard therapeutic method for colorectal lesions 
worldwide. 
In this review we discuss the therapeutic strategies available to manage non-polypoid 
early cancer of the colon and rectum, with particular regard to differences in Eastern and 
Western practice. 
EMR or ESD? The western position 
Several methods of EMR have been described. The most common is the ‘strip biopsy 
method’. With this technique a liquid is injected into the submucosa below the lesion to 
create a ‘cushion’ to carry out the snare polypectomy. Different EMR solutions have been 
described. In general, more viscous solutions such as succinylated gelatine, hydroxy-
propyl-methyl-cellulose [14], hyaluronic acid [15] or dextrose [16] are preferred as they last 
longer. In most cases, a small amount of adrenaline is added making a 0.5% solution 
together with indigo carmine to achieve a light bluish colour. The adrenaline reduces 
immediate oozing from small vessles during the procedure but does not reduce the risk of 
delayed bleeding [17]. The dye added to the solution allows the extent of lift to be 
ascertained. 
The ‘pull within the snare’ (‘grasp and snare’) technique, less commonly used requires a 
double channel endoscope as it uses a grasping forceps to pull the lesion into the snare. 
The technique allows otherwise unresectable or poorly lifting lesions to be removed, but 
the ‘pull within the snare’ technique is associated with a higher risk of perforation [18]. 
Whereas ESD has the clear advantage of achieving a single specimen, allowing for more 
accurate histological assessment and lower risk of recurrence, the general perception in 
the western scientific community is that it is a more complex technique, requiring greater 
experience, longer procedure time, higher risk of complications, the need for admission 
and the availability of specialised equipment including carbon dioxide insufflation and, 
usually in the West, general anaesthesia with all that this entails. 
A recent comparative study [19] demonstrated that there was a higher en bloc resection 
rate of 83.5% with colorectal ESD compared with 48.1% for lesions removed by EMR, but 
in this study, ESD was associated with greater risk of perforation than when lesions were 
removed by EMR (5.9% vs 0%). This was confirmed in an analysis of 17 case series 
(n = 1858) in which the overall risk of perforation complicating an EMR was found to be 
0.2% [20]. The largest ESD experience published in Europe [21] reports perforation rates 
up to 18%. Furthermore, the equipment used for ESD is expensive, an important 
consideration for National Health Care Systems. The pros and cons of ESC and EMR are 
shown in Table 1. 
Table 1. Comparison of endoscopic mucosal resection (EMR) and endoscopic submucosal 
dissection (ESD) 
  EMR ESD 
Cost Cheap Expensive 
Technique Less complex More Complex 
Duration Short Long 
Bleeding risk < 1% 2% 
Perforation risk < 1% 5–18% 
Table 1. Comparison of endoscopic mucosal resection (EMR) and endoscopic submucosal 
dissection (ESD) 
  EMR ESD 
Need for inpatient 
care Not usually needed Up to 5 days normally 
Need for CO2 
insufflation Not needed Needed 
Sedation Conscious sedation/rarely general 
anaesthetic 
In Japan conscious sedation/general 
anaesthetic rare 
In the West general anaesthetic more 
common 
En bloc resection Not possible if piecemeal EMR Usually possible 
EMR or ESD ? The eastern position 
There is increasing evidence that well differentiated cancers invading up to 1000 μm 
beyond the muscularis mucosae without lymphovascular invasion have a minimal risk of 
lymph node metastasis [22] and can be cured by local excision alone. Lymphovascular 
invasion and poor differentiation are detected following histopathological examination of 
the resection specimen, but the vertical depth of invasion may be estimated by the 
appearance of the lesion during endoscopy. 
EMR is an effective minimally invasive technique for early stage lesions. The ‘inject and 
cut’ method is simple and safe and is used widely. Lesions that do not lift during 
submucosal injection are generally not candidates for local excision. Due to the size of 
snares, EMR cannot be used to remove lesions larger than 20 mm in one piece, which 
prevents precise histopathological assessment and increases the risk of local recurrence. 
The estimation of the depth of cancer invasion before treatment is not always reliable, 
although it is crucial to decide the therapeutic strategy. Magnifying chromoendoscopy is a 
validated method that facilitates detailed analysis of the morphological architecture of 
colonic mucosal crypt orifices (pit pattern) in a simple and efficient manner. The clinical 
classification of the colonic pit pattern (invasive and non-invasive) by using magnifying 
chromoendoscopy was originally described by Fujii with the aim to discriminate between 
intramucosal-submucosal superficial invasion and submucosal deep invasion [23] (Fig. 1). 
An invasive pattern is characterized by irregular and distorted pits observed in a 
demarcated area suggesting submucosal deep invasion (? 1000 μm). At the National 
Cancer Center Hospital (NCCH) in Japan, the indication for en bloc resection is 
considered as follows: laterally spreading tumour (LST) non-granular type (LST-NG) lesion 
? 20 mm and LST granular (LST-G) type lesion ? 30 mm, which have higher submucosal 
invasion rates (Table 2) [24]. In particular, the LST-NG type lesion ? 20 mm is technically 
difficult to remove completely even by piecemeal EMR and these lesions are regarded as 
a ‘definite indication for en-bloc resection’. In contrast, LST-G type lesions ? 30 mm are 
considered a ‘relative indication for en-bloc resection’. Moreover, large villous tumours, 
recurrent lesions, and residual intramucosal lesions showing non-lifting after EMR may 
also be considered potential candidates for ESD. 
Table 2. Relationship betweens size of laterally spreading tumour (LST) and incidence of 
submucosal invasion. National Cancer Center Hospital, Tokyo, 1998–2006 
  10 mm (%) 20 mm (%) 30 mm (%) 40 mm (%) Total (%) 
1. a 
LST-G: laterally spreading tumour, granular type. 
2. b 
LST-NG: laterally spreading tumour, non-granular type. 
IIa (LST-Ga): LST-G, 
uniform type 0/115 (0) 0/70 (0) 1/31 (3.2) 0/13 (0) 1/229 (0.4) 
Is+IIa (LST-G): LST-G, 
mixed type 4/72 (5.6) 6/70 (8.6) 9/65 (13.8) 
25/114 
(21.9) 
44/321 
(13.7) 
IIa (LST-NGb) 12/246 (4.9) 24/106 (22.6) 11/33 (33.3) 8/17 (47.0) 
55/402 
(13.7) 
 
Figure 1. Colorectal Endoscopic Submucosal Dissection (ESD). (a, b) 30 mm, IIa+IIc 
lesion located in rectum (Ra). (c) Magnifying chromoendoscopy revealed non-invasive 
pattern. (d, e) After injection of glycerol and sodium hyaluronic acid into submucosal layer, 
circumferential incision was made using bipolar needle knife (B-knife) and performed 
submucosal dissection using both B-knife and insulation-tipped (IT) knife. (f) Ulcer bed 
after en bloc resection. (g) En bloc resected specimen. (h) Histopathology revealed 
superficial submucosal cancer (SM: 800 μm with no lymphovascular invasion, negative cut 
margin). 
ESD is undoubtedly one of the best methods to achieve en bloc resection. At the NCCH, 
ESD procedures are primarily performed using a bipolar needle-knife (B-knife) (Xeon 
Medical Co, Tokyo, Japan) [25] or an insulated-tip (IT) knife (Olympus Co, Tokyo, Japan). 
Carbon dioxide (CO2) insufflation is preferred to air insufflation to reduce patient discomfort 
[12, 26, 27]. Lesion margins are delineated before ESD by using 0.4% indigo-carmine dye 
spraying. After injection of Glyceol® (10% glycerol and 5% fructose in normal saline 
solution) [28] and sodium hyaluronate acid into the submucosal layer [15], a 
circumferential incision is made using the B-knife and ESD is then carried out using both 
the B-knife, and IT-knife. In some selected colorectal lesions measuring 20–30 mm in 
diameter, snaring EMR after circumferential mucosal incision (CEMR) technique is 
possible [29], and has the advantage to reduce significantly the duration of the procedure. 
Between January 2000 and December 2006 11 488 colorectal neoplasms (excepting 
advanced cancers) in 6369 patients were treated endoscopically or surgically at the 
NCCH. To clarify the prevalence of ‘definite indication for colorectal ESD’, we reviewed 
and analysed records from our database. There were 9797 adenomas and 1691 early 
colorectal cancers (intramucosal cancer: 1294, submucosal cancer: 397). Among all 
neoplastic lesions, the prevalence of LSTs (LST-G and LST-NG) and the proportion for 
which ESD would have been indicated were 5.9% and 2.6% (Table 3). In contrast, among 
all early cancers, the prevalence of LSTs was 22.6% and the proportion for which ESD 
would have been indicated was 15.2% [LST-NG, ? 20 mm: 5.0% and LST-G (mixed type), 
? 30 mm: 10.2%]. Moreover, the prevalence of ‘definite indication for ESD: LST-NG, 
? 20 mm’ among all neoplastic lesions and all early cancers was 1.0% (115/11 488) and 
5.0% (85/1691). 
Table 3. Prevalence of LSTs and indicated lesions for ESD National Cancer Center Hospital, 
Tokyo, 2000–2006 
  All neoplastic lesions % (n = 11 488) 
Early colorectal cancers % 
(n = 1691) 
1. a 
LSTs: LST-G and LST-NG. 
2. b 
Definite indication: LST-NG lesion ? 20 mm. 
3. c 
Relative indication: LST-G Mixed type [Is+IIa (LST-G)] ? 30 mm. 
LSTsa 5.9 (n = 674) 22.6 (n = 382) 
Table 3. Prevalence of LSTs and indicated lesions for ESD National Cancer Center Hospital, 
Tokyo, 2000–2006 
  All neoplastic lesions % (n = 11 488) 
Early colorectal cancers % 
(n = 1691) 
Indication for ESD 2.6 (n = 294) 15.2 (n = 258) 
Definite indicationb for 
ESD 1.0 (n = 115) 5.0 (n = 85) 
Relative indicationc for 
ESD 1.6 (n = 179) 10.2 (n = 173) 
We evaluated the clinical outcome of ESD performed by trainees and clarified the learning 
curve for this procedure [30]. In order to perform colorectal ESD, trainees must show 
competence in the non-loop insertion colonoscopy technique, in conventional or piecemeal 
EMR techniques, and experience with over 20 gastric ESD cases and assistance during 
more than 20 colorectal ESDs conducted by an experienced endoscopist. Since gastric 
cancer is less common than colorectal cancer in Western countries, trainees should begin 
clinical training with lower rectal lesions, which have a lower risk of perforation and have a 
diathermy setting similar to that of gastric lesions. With these expedients, colorectal ESD 
can be performed without serious complication even by trainee endoscopists under the 
guidance of experienced specialists, untill they gain experience of over 30 cases. 
Post-polypectomy surveillance 
Patients with adenomas are at increasing risk of metachronous adenomas or cancers, 
which may develop within 3–5 years of colonoscopy and polypectomy, so called interval 
cancers. The recommendations for surveillance do not apply to patients with hereditary 
colorectal syndromes or inflammatory bowel disease. If no adenoma or polyp is detected 
at screening endoscopy, the European Society of Gastroenterology (ESGE) 
recommendation is to repeat examination at 10 years [52]. If small (< 10 mm) hyperplastic 
polyps, or one to two tubular adenomas < 10 mm with low grade dysplasia are detected, 
these should be considered low risk and a repeat colonoscopy at 10 years is 
recommended [53-57]. An adenoma with villous histology or high grade dysplasia or one 
over 10 mm in diameter or where these are three or more should be considered high risk 
and a surveillance colonoscopy at 3 years is recommended. Patients with ten or more 
adenomas should be referred for genetic counseling. Epidemiological studies have 
indicated that high-risk groups had a 3.6–6.6 fold increase in developing colorectal cancer 
(CRC) compared with the general population [58, 59], with a high efficacy of endoscopic 
surveillance in reducing the cancer risk [60-62]. Serrated polyps < 10 mm with no 
dysplasia polyps should be classified as low risk, while those more than 10 mm or with 
dysplasia, should be considered high risk. In the case of piecemeal resection of an 
adenoma over 10 mm, endoscopic follow up within 6 months is recommended. Inadequate 
polypectomy has been reported in up to 17% of lesions over 10 mm [63]. A normal 
macroscopic appearance of the polypectomy site and a negative scar biopsy at the first 
follow-up, have been shown to be predictive of long term eradication [64]. 
The ESGE found insufficient evidence to provide recommendations on post- polypectomy 
surveillance based on other potential risk factors such as age or family history of CRC. 
Age is a strong risk factor for metachronous advanced neoplasia. The risk is almost three 
times greater among individuals older than 80 years compared with those between 50 and 
59, which was no different from those aged 60–69 years [65]. Older people could be more 
prone to complications of colonoscopy, and the potential benefit of endoscopic 
surveillance may be limited by reduced life expectancy, especially when the estimated 10–
20 years duration of the adenoma-carcinoma sequence is considered. No study has 
assessed the optimal age for stopping surveillance. Statistical simulations indicate that 
surveillance should cease at 85 years [66], other recommendations should be 
individualized, based on general health status and comorbidity [67]. 
The ESGE recommends an an early repeat of colonoscopy or a shorter surveillance 
interval in patients in whom inspection of the colonic mucosa was inadequate through poor 
bowel preparation which is associated with a higher risk of missed lesions. The post 
polypectomy guidelines of the ESGE and the US Multi Society Task Force (US MSTF) are 
the same [68]. Further studies especially regarding serrated lesions are mandatory. 
In Western countries, many units have concluded that piecemeal resection of rectal 
lesions is no longer acceptable. This is the reason why many surgeons are favouring 
transanal single fragment resection over piece-meal EMR. If ‘single-fragment resection’ is 
the correct procedure in the rectum, it must also be correct elsewhere in the 
gastrointestinal tract. In the rectum, truly minimally invasive organ preserving surgery, 
such as the transanal approach, may offer a better alternative to radical resectional 
surgery. Supporters of piecemeal resection, even in the rectum, assert that in the case of 
larger lesions, endoscopic resection is quicker, safer and cheaper than surgical resection. 
The advantage of ESD is that a single fragment resection potentially allows for a more 
accurate histological assessment of invasion. As with laparoscopic resection, ESD takes 
more time than EMR costs more and is more liable to complications. Moving from EMR to 
ESD would have far reaching implications, not least in training. As the risk of lymph node 
metastases is very low with T1 colorectal cancers, a move to ESD means that all small 
colorectal cancers would first be resected endoscopically. If the histolpathogical 
examination found lymphovascular invasion, poor differentiation or extensive tumour 
budding a colectomy would then be advised. 
In Eastern countries, supporters of ESD consider it is to be an ideal method to provide ‘en 
bloc resection’ even for large colorectal lesions, but the prevalence of lesions with a 
‘definite indication for ESD’ among all colorectal neoplasms is small. Colorectal ESD 
should be performed by experienced well-trained endoscopists and trainee endoscopists 
should focus on mastering the more fundamental techniques of cold or hot snare 
polypectomy, conventional EMR and single block or piecemeal EMR and have knowledge 
of the surveillance strategy after endoscopic treatment. Characteristic colonoscopic 
findings obtained by magnifying chromoendoscopy are useful for determination of the 
invasion depth of early stage colorectal cancers, which is an essential factor in selecting a 
treatment modality between endoscopic treatment and surgery. As new therapeutic 
techniques are developed, preoperative endoscopic diagnosis will become increasingly 
important. 
The rectum offers the further option of transanal endoscopic surgery. TEM entails the true 
concept of minimally invasiveness and differs from colectomy, which even when performed 
laparoscopically is still major surgery. In a comparison of techniques, we performed a 
systematic review of published series and showed an advantage for TEM compared with 
ESD in achieving an R0 resection. 
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